Sandoz buys into Durect's long-acting painkiller

Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.

The first decade of biosimilars – and beyond

Sandoz’s CEO Richard Francis on the latest developments in biosimilars.

Enbrel unlikely to face Novartis rival until 2018

Amgen arguing that US patent will last until 2029.

Exclusive: Frontiers Health – Day two coverage

Frontiers Health is a two-day event focused on disruptive health; innovative technology, application of digital and new ideas which can, are and will transform the face

Exclusive: Frontiers Health - Day one coverage

Sandoz mhealth hack to address healthcare access

Sandoz HACk is encouraging 18-35 year olds to “re-imagine” healthcare.